Monday, April 6, 2020
Home Innovation That Matters

Innovation That Matters

M3 Biotechnology Charts its Own Unique Course in the Fight Against Alzheimer’s

The costs of neurodegenerative diseases are enormous, with Alzheimer’s disease being the most common affliction. The economic burden of this disease is well over $100 billion in the US. What’s more is current drugs offer only symptomatic relief and many clinical trials have ended...

Canada Sees Biotech as Key Asset and Priority for its Economic Growth

While the US is recognized as the dominate player in the global biotech sector, its Canadian neighbor to the north also recognizes the strategic importance of biotech as a key economic driver for the country, and its critical role in the economy. Helping to...

Michael J. Fox Foundation CEO Sees ‘Significant Progress’ in Treating Causes of Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) invests nearly 90% of its spending to find a cure for the debilitating neurodegenerative disease, totaling more than $800 million since its founding in 2000, including $100 million in 2017. MJFF CEO Todd Sherer, Ph.D., notes...

RAPT Therapeutics Sees “Charged” Lung Cancer Tumors as Inviting Targets for Lead Drug FLX475

Lung cancer remains a stubborn disease to treat. Even cutting-edge immuno-therapies have had limited success. Brian Wong, CEO of South San Francisco-based RAPT Therapeutics, believes that the company’s lead drug, FLX475, has potential to overcome the scientific challenges in treating this disease.

Genentech’s New Combination Chemotherapy Prolonged Breast Cancer Patient Lives for Extra 16 Months

A phase III clinical trial sponsored by Genentech using a combination of chemotherapy drugs showed unprecedented results in patients with metastatic HER2-positive breast cancer.  The outcome of this study is published in the February issue of the prestigious New England Journal of Medicine.  The...




Twitter LinkedIn 


WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted...